Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
  • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
  • Contact Us
  • Menu Menu
You are here: Home

Developing T-Cell Adaptive Vaccines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen-infected cells.

Introducing Emergex Vaccines

Emergex Vaccines is a clinical-stage, privately held biotechnology company headquartered near Oxford, UK, with R&D facilities in Milton Park, UK and an operating subsidiary in Doylestown, Pennsylvania, USA. Emergex Vaccines is focussed on developing a range of 100% synthetic CD8+ T cell Adaptive Vaccines that harness the body’s natural cellular immune response to destroy pathogen-infected cells and to provide immune protection for some of the world’s most impactful diseases.


Our Technology Vaccine Advantages

We work on addressing some of the world’s most immediate health threats (including viral diseases such as Dengue Fever, COVID-19, Zika, Ebola and pandemic Influenza, as well as serious intracellular bacterial infections) and have a growing pipeline of vaccine candidates.

Our Vision:

To positively impact global human health though the development of next generation vaccines for some of the world’s most immediate health threats.

Our Technology Vaccine Advantages

Latest press releases

Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine

28th July 2022
Read more
/wp-content/uploads/2018/01/logo.png 0 0 gatekeeper /wp-content/uploads/2018/01/logo.png gatekeeper2022-07-28 07:00:122022-07-28 07:58:39Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine

Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil

1st July 2022
Read more
/wp-content/uploads/2018/01/logo.png 0 0 gatekeeper /wp-content/uploads/2018/01/logo.png gatekeeper2022-07-01 07:00:062022-06-30 16:22:37Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil

Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch

17th May 2022
Read more
/wp-content/uploads/2018/01/logo.png 0 0 gatekeeper /wp-content/uploads/2018/01/logo.png gatekeeper2022-05-17 12:00:502022-05-17 13:12:39Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
Our Technology Vaccine Advantages

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top